Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (13978)	7/4/2000 7:11:15 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

P II subjects also got at least 2 units of blood. P II showed "benefits" with possibility of statistical error. Also if bood really gives you bpi, and blodd is an approved product, why will blood not be used as a cheaper source of bpi?

To: Robert K. who wrote (13978)	7/4/2000 8:04:15 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

Overnight? Please define overnight. The LLY license to XOMA technology was announced on May 5, 1997. I do not know when it was signed. Indeed the signing did not occur overnight. <g> LLY must have said we want to sign this agreement for some purpose. The purpose was not because they liked XOMA. I would suspect someone at LLY said this is something we could use because it will provide x benifits. Others crapped all over the idea saying look at the additional cost. But a decision was made to check out the technology in detail. Perhaps LLY even contacted another company that actually used the technology, to check out their experience with it, perhaps not. In any event LLY bought into the technology. When did LLY start its' trial? "Lilly's 1,520-patient sepsis study, known as Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis, began in July 1998 and was conducted at clinical centers in 11 countries" Humm! May 5, 1997 until July, 1998. Overnight? Is is? BTW I have no idea if LLY used the XOMA technology. I am adamant that XOMA should tell shareholders, if they did or did not. Or if all they can say, is that they are prohibited from saying, by the terms of the agreement, that will do also.